Drug Profile


Alternative Names: KSS-694; Salagen Granules; Salagen Tab.

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MGI Pharma
  • Developer Eisai Co Ltd; Kissei Pharmaceutical; Pfizer
  • Class Alkaloids; Antiglaucomas; Furans; Imidazoles; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Xerostomia

Most Recent Events

  • 22 May 2015 Merus Labs enters into an agreement with Novartis Pharma for manufacturing and commercialisation of pilocarpine in Europe
  • 12 Dec 2014 Launched for Xerostomia in Japan (PO, Granules)
  • 31 Oct 2012 Actavis has been acquired and merged into Watson Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top